Information Provided By: 
Fly News Breaks for May 2, 2017
AEZS
May 2, 2017 | 08:19 EDT
Maxim analyst Jason Kolbert removed ZoptEC from his Aeterna Zentaris model after the drug's Phase 3 study in metastatic endometrial cancer did not achieve its primary endpoint and cut his price target accordingly to $2 from $11. However, he keeps a Buy rating on Aeterna Zentaris shares as the company moves closer to filing the NDA for Macrilen, which is expected in Q3. Aeterna Zentaris shares fell $2.00, or roughly 60%, to $1.35 yesterday.
News For AEZS From the Last 2 Days
There are no results for your query AEZS
